Investigating biomarkers for acute kidney injury (AKI) progression after cardiac surgery associated AKI
- Conditions
- N17Acute renal failure
- Registration Number
- DRKS00021435
- Lead Sponsor
- niversitätsklinikum MünsterKlinik für Anästhesiologie, operative Intensivmedizin und Schmerztherapie
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
patients with AKI defined as KDIGO stage2/3 within 72h after on-pump cardiac surgery
- 18-90 years
- informed consent
Exclusion Criteria
- Prior kidney transplant
- dialysis dependent CKD
- History of human deficiency virus (HIV) or hepatitis virus (Hepatitis C)
- pregnancy or nursing period
- off-pump heart surgery
- hepatorenal syndrome
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Predictive value of CCL14 for persistent AKI within 72h. In addition, the primary endpoint is met if the criteria mortality or dialysis dependency are met.<br>Persistent KDIGO stage 3 (yes/no) is defined as follows. For patients enrolled at stage 2, persistent severe AKI yes” requires an AKI progression to stage 3 within 48 hours and a persistence at stage 3 for at least 72 hours; otherwise severe AKI is considered not persistent. For patients enrolled at stage 3, persistent severe AKI yes” requires a persistence at stage 3 for 72 hours from the time of sample collection; otherwise severe AKI is considered not persistent<br>
- Secondary Outcome Measures
Name Time Method - MAKE at day 30 and 90<br>- renal recovery at day 30 and 90<br>- dialysis dependency at day 30 and 90<br>- mortality on Day 30 and 90<br>- persistent severe AKI min. 72 h<br>- Length of hospital and ICU stay<br><br>